Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021
Hou FF, et al.; for the MAIN Trial Investigators. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: A randomized clinical trial. JAMA Netw Open 2023; 6:e2254054. doi: 10.1001/jamanetworkopen.2022.54054
Hou JH, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: A randomized controlled trial. Am J Kidney Dis 2017; 69:788–795. doi: 10.1053/j.ajkd.2016.11.027
Chen X, et al. [A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy.] Zhonghua Yi Xue Za Zhi 2002; 82:796–801. PMID: 12126522; https://pubmed.ncbi.nlm.nih.gov/12126522/
Maes BD, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65:1842–1849. doi: 10.1111/j.1523-1755.2004.00588.x
Frisch G, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20:2139–2145. doi: 10.1093/ndt/gfh974
Tang SCW, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77:543–549. doi: 10.1038/ki.2009.499
Lv J, et al.; TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2022; 327:1888–1898. doi: 10.1001/jama.2022.5368
Dooley MA, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1895. doi: 10.1056/NEJMoa1014460
Werth VP, et al.; PEMPHIX Study Group. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med 2021; 384:2295–2305. doi: 10.1056/NEJMoa2028564